CONNECT WITH US
Social Media

Social Media

NHS data contract to stay with Palantir until 2029

BBC News – Social Media logo

Published on

Add as a preferred source on Google
NHS data contract to stay with Palantir until 2029

The government says it will continue a key NHS data contract in England with the controversial US tech giant Palantir until 2029, rather than triggering an early release clause next year.

But ministers are inviting British firms to bid for the contract from 2029, with a procurement programme beginning next summer.

A Commons Committee had called on the government to part ways and appoint a company "more compatible with UK values". Protesters regularly target Palantir over Israel's use of its technology in the Gaza conflict and oppose its use in US immigration enforcement.

The £330m deal, which began in 2024 to help manage hospital waiting lists in England, was due to run until 2031.

The prime minister had faced pressure from some Labour MPs to cut ties with Palantir. They said they were extremely disappointed by the decision, calling the contract "an albatross" hanging around the NHS's neck.

There have also been concerns raised about how patient data will be used.

Palantir, which was co-founded by billionaire Peter Thiel, has interests in US defence and security, and has contracts with the Israeli military.

Health minister James Frith said the move was "not about the politics of executives of suppliers, nor is it about the territories or customers that one company or one supplier makes".

The government says UK companies will be encouraged to tender to avoid overdependence on one supplier.

The timeframe is not fast enough for some members of the government.

Dame Chi Onwurah, Labour MP for Newcastle upon Tyne Central and West, said the government needed to "act urgently" to procure "credible domestic alternatives".


Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.